{"transactions":[{"id":712534,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-07-09T01:04:01.000Z","date":"2026-07-07","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":37500,"derivative":{"exercise_price":2.7,"expiration_date":"2036-07-07","underlying":"Common stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001104659-26-082011","document":"tm2620095-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926082011/tm2620095-3_4seq1.xml","form_type":"4"}},{"id":833310,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-19T20:05:29.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":10142,"price":0.815,"value":8265.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of previously granted restricted stock units (\"RSUs\"). Such \"sale to cover\" was automatically effected to satisfy tax withholding obligations and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.783 to $0.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":151669,"source":{"system":"sec-edgar","filing":"0000905148-26-001397","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000090514826001397/form4.xml","form_type":"4"}},{"id":1067674,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-08-13T23:48:49.000Z","date":"2025-08-13","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.29,"value":64500.0,"ownership":{"direct":true},"balance_after":161811,"source":{"system":"sec-edgar","filing":"0000905148-25-002877","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000090514825002877/form4.xml","form_type":"4"}},{"id":1195541,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-20T22:08:37.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":6939,"price":3.1793,"value":22061.1627,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover tax withholding due upon vesting of previously granted restricted stock units (\"RSUs\"). Such \"sale to cover\" was automatically effected to satisfy tax withholding obligations and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $3.14 to $3.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":111811,"source":{"system":"sec-edgar","filing":"0000905148-25-000984","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000090514825000984/form4.xml","form_type":"4"}},{"id":1199326,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-19T00:33:27.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest on March 14, 2026, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":3.29,"expiration_date":"2035-03-13","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000905148-25-000962","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000090514825000962/form4.xml","form_type":"4"}},{"id":1199325,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-19T00:33:27.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 14, 2026, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":118750,"source":{"system":"sec-edgar","filing":"0000905148-25-000962","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000090514825000962/form4.xml","form_type":"4"}},{"id":1263513,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-02-18T21:07:24.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on February 14, 2026, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":90000,"derivative":{"exercise_price":0.29,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001104659-25-014757","document":"tm256830-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925014757/tm256830-8_4seq1.xml","form_type":"4"}},{"id":1475020,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-06-18T21:01:29.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option was contingently granted on December 22, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders.  Such stockholder approval was obtained on June 14, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in full on December 22, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":90000,"derivative":{"exercise_price":2.58,"expiration_date":"2033-12-22","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001104659-24-072882","document":"tm2417520-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924072882/tm2417520-4_4seq1.xml","form_type":"4"}},{"id":1568180,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T22:18:37.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this option shall vest on March 15, 2025, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":225000,"derivative":{"exercise_price":4.31,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001415889-24-008636","document":"form4-03192024_100330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000141588924008636/form4-03192024_100330.xml","form_type":"4"}},{"id":1568179,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-19T22:18:37.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":81250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 15, 2025, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":81250,"source":{"system":"sec-edgar","filing":"0001415889-24-008636","document":"form4-03192024_100330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000141588924008636/form4-03192024_100330.xml","form_type":"4"}},{"id":1842610,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-06-28T22:27:07.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in full on June 28, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":71925,"derivative":{"exercise_price":1.85,"expiration_date":"2033-06-28","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001104659-23-075942","document":"tm2320030-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923075942/tm2320030-5_4seq1.xml","form_type":"4"}},{"id":1936715,"issuer":{"id":6608,"kind":"organization","name":"MAXCYTE, INC."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-28T14:06:49.000Z","date":"2023-03-27","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on March 27, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date."}],"balance_after":350000,"derivative":{"exercise_price":4.11,"expiration_date":"2033-03-26","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-23-021333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1287098/000120919123021333/doc4.xml","form_type":"4"}},{"id":2198957,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-08-01T22:01:54.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option shall vest in full on June 24, 2023, subject to the reporting person's continued service through the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022."}],"balance_after":11700,"derivative":{"exercise_price":4.1,"expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":11700},"source":{"system":"sec-edgar","filing":"0001104659-22-084839","document":"tm2222253-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922084839/tm2222253-5_4seq1.xml","form_type":"4"}},{"id":2570593,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T20:00:56.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":25000,"price":1.04,"value":26000.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001104659-21-115477","document":"tm2127646-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465921115477/tm2127646-1_4seq1.xml","form_type":"4"}},{"id":2644117,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-07-02T20:04:10.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":117000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest on the first anniversary of the date of grant."}],"balance_after":117000,"derivative":{"exercise_price":1.19,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001104659-21-088842","document":"tm2120855-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465921088842/tm2120855-6_4seq1.xml","form_type":"4"}},{"id":3038719,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (right to buy)","published_at":"2020-09-03T22:48:57.000Z","date":"2020-09-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments beginning on 10/01/2020, such that the option will be fully vested on the third anniversary of the date of grant."}],"balance_after":60000,"derivative":{"exercise_price":6.04,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-20-102336","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1375884/000110465920102336/a4.xml","form_type":"4"}},{"id":3099659,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-06-25T20:22:18.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant shall vest over a period of three years from the grant date, with one-third vesting on  the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a  24 month period beginning on the first anniversary of the grant date."}],"balance_after":80000,"derivative":{"exercise_price":1.28,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-20-076871","document":"tm2023456d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465920076871/tm2023456d3_4.xml","form_type":"4"}},{"id":3343093,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":1.94,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3343092,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":2.36,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3343091,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":16.55,"expiration_date":"2027-06-22","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3343090,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":2400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":14.25,"expiration_date":"2026-06-22","underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3343089,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":2400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":81.6,"expiration_date":"2025-06-24","underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3343088,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":1200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":62.1,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3343087,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":1600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":82.35,"expiration_date":"2023-07-19","underlying":"Common Stock","underlying_shares":1600},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3343086,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-12-13T16:17:13.000Z","date":"2019-12-13","kind":"disposition_to_issuer","acquired":false,"shares":534,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the \"Merger Agreement\"), among Fibrocell Science, Inc. (the \"Company\"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00."}],"balance_after":0,"derivative":{"exercise_price":56.25,"expiration_date":"2023-03-04","underlying":"Common Stock","underlying_shares":534},"source":{"system":"sec-edgar","filing":"0001628280-19-015081","document":"wf-form4_157627181620899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019015081/wf-form4_157627181620899.xml","form_type":"4"}},{"id":3489377,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-06-14T20:31:59.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest on the one year anniversary of the date of grant."}],"balance_after":9750,"derivative":{"exercise_price":2.15,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0001144204-19-031006","document":"tv523607_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000114420419031006/tv523607_4.xml","form_type":"4"}},{"id":3490626,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-06-14T16:25:49.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the shares vest and become exercisable on the earlier of (x) June 12, 2020 and (y) the date of the Company's 2020 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 12, 2021 and (y) the date of the Company's 2021 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates."}],"balance_after":12000,"derivative":{"exercise_price":1.94,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001628280-19-008004","document":"wf-form4_156054393476617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828019008004/wf-form4_156054393476617.xml","form_type":"4"}},{"id":3682472,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-01-30T12:32:24.000Z","date":"2019-01-29","kind":"purchase","acquired":true,"shares":50000,"price":0.6344,"value":31720.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price of $0.6344 per share represents a weighted average of purchase prices ranging from $0.6097 to $0.6386 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001140361-19-001802","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036119001802/form4.xml","form_type":"4"}},{"id":3760684,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-11-16T21:54:02.000Z","date":"2018-11-14","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the option vests and becomes exercisable on November 14, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month following such date until fully vested."}],"balance_after":500000,"derivative":{"exercise_price":1.09,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001140361-18-043286","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036118043286/form4.xml","form_type":"4"}},{"id":3791011,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-10-15T23:49:39.000Z","date":"2018-10-12","kind":"grant","acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant was divided into a definitive grant of 6,150 shares, which vest in equal monthly installments over a seven month period from the grant date, and a contingent grant of 13,350 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest immediately upon such stockholder approval."}],"balance_after":19500,"derivative":{"exercise_price":2.61,"expiration_date":"2028-10-12","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001144204-18-053878","document":"tv504843_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000114420418053878/tv504843_form4.xml","form_type":"4"}},{"id":3886629,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-06-21T16:07:51.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the shares vest and become exercisable on the earlier of (x) June 19, 2019 and (y) the date of the Company's 2019 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 19, 2020 and (y) the date of the Company's 2020 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates."}],"balance_after":6000,"derivative":{"exercise_price":2.36,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-18-008176","document":"wf-form4_152961165477562.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828018008176/wf-form4_152961165477562.xml","form_type":"4"}},{"id":3920941,"issuer":{"id":161208,"kind":"organization","name":"PERNIX THERAPEUTICS HOLDINGS, INC.","symbol":"PTX"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-23T17:28:16.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in four equal annual installments of 6,250 shares over a four-year period, with the first installment vesting on May 22, 2019, which is the one-year anniversary of the grant date."}],"balance_after":25000,"derivative":{"exercise_price":2.63,"expiration_date":"2028-05-21","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001136261-18-000143","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024126/000113626118000143/primary_doc.xml","form_type":"4"}},{"id":4107111,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"officer":true,"officer_title":"President and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-04T21:56:09.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the option vests and becomes exercisable on January 2, 2019, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month following such date until fully vested."}],"balance_after":250000,"derivative":{"exercise_price":2.1,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001140361-18-000861","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036118000861/form4.xml","form_type":"4"}},{"id":4158779,"issuer":{"id":161208,"kind":"organization","name":"PERNIX THERAPEUTICS HOLDINGS, INC.","symbol":"PTX"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-11-17T14:23:33.000Z","date":"2017-11-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in four equal annual installments of 12,500 shares over a four-year period, with the first installment vesting on November 15, 2018, which is the one-year anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":2.97,"expiration_date":"2027-11-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001136261-17-000283","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1024126/000113626117000283/primary_doc.xml","form_type":"4"}},{"id":4272992,"issuer":{"id":153085,"kind":"organization","name":"Fibrocell Science, Inc.","symbol":"FCSC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2017-06-26T19:34:57.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the shares vest and become exercisable on the earlier of (x) June 22, 2018 and (y) the date of the Company's 2018 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 22, 2019 and (y) the date of the Company's 2019 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates."}],"balance_after":30000,"derivative":{"exercise_price":3.31,"expiration_date":"2027-06-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001628280-17-006738","document":"wf-form4_149852008378559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/357097/000162828017006738/wf-form4_149852008378559.xml","form_type":"4"}},{"id":4276493,"issuer":{"id":175088,"kind":"organization","name":"GENVEC INC","symbol":"GNVC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2017-06-20T16:33:23.000Z","date":"2017-06-16","kind":"exercise","acquired":false,"shares":25000,"price":5.6,"value":140000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger."}],"balance_after":0,"derivative":{"exercise_price":5.6,"exercise_date":"2017-06-16","expiration_date":"2017-06-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001123292-17-001160","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/934473/000112329217001160/edgar.xml","form_type":"4"}},{"id":4276492,"issuer":{"id":175088,"kind":"organization","name":"GENVEC INC","symbol":"GNVC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-06-20T16:33:23.000Z","date":"2017-06-16","kind":"disposition_to_issuer","acquired":false,"shares":29320,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation (\"Intrexon\") and Intrexon GV Holding, Inc. (the \"Merger Agreement\") in exchange for (i) 8,708 shares of Intrexon common stock having a market value of $198,717 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the \"Merger Consideration\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"[footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. (\"Novartis\") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001123292-17-001160","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/934473/000112329217001160/edgar.xml","form_type":"4"}},{"id":4276491,"issuer":{"id":175088,"kind":"organization","name":"GENVEC INC","symbol":"GNVC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-06-20T16:33:23.000Z","date":"2016-06-16","kind":"tax_withholding","acquired":false,"shares":20930,"price":7.19,"value":150486.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Withholding of Common Stock to pay exercise price and to satisfy tax withholding obligations."}],"balance_after":29320,"source":{"system":"sec-edgar","filing":"0001123292-17-001160","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/934473/000112329217001160/edgar.xml","form_type":"4"}},{"id":4276490,"issuer":{"id":175088,"kind":"organization","name":"GENVEC INC","symbol":"GNVC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-06-20T16:33:23.000Z","date":"2017-06-16","kind":"exercise","acquired":true,"shares":25000,"price":5.6,"value":140000.0,"ownership":{"direct":true},"balance_after":50250,"source":{"system":"sec-edgar","filing":"0001123292-17-001160","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/934473/000112329217001160/edgar.xml","form_type":"4"}},{"id":4297890,"issuer":{"id":7572,"kind":"organization","name":"Cellectar Biosciences, Inc."},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-06-01T22:01:24.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in equal annual increments over a period of three years from the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":1.74,"expiration_date":"2027-05-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001144204-17-030679","document":"v468267_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279704/000114420417030679/v468267_4.xml","form_type":"4"}},{"id":4601939,"issuer":{"id":175088,"kind":"organization","name":"GENVEC INC","symbol":"GNVC"},"owners":[{"id":31408,"kind":"person","name":"Swirsky Douglas J","position":1,"cik":"0001375884","reported_name":"Swirsky Douglas J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2016-09-16T15:09:53.000Z","date":"2016-09-16","kind":"purchase","acquired":true,"shares":10000,"price":0.5,"value":5000.0,"ownership":{"direct":true},"balance_after":252500,"source":{"system":"sec-edgar","filing":"0001140361-16-080023","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/934473/000114036116080023/doc1.xml","form_type":"4"}}]}